Recently, clinical trials were conducted to target protein kinases in liposarcoma, including CDK4 inhibitor palbociclib (PD0332991), pan-CDK inhibitor flavopiridol, vascular endothelial growth factor receptor (VEGFR) inhibitor sorafenib, multi-kinase inhibitor regorafenib, and vascular endothelial growth factor A (VEGF-A) monoclonal antibody bevacizumab [15–19]. The gene discussed is VEGFA; the disease is liposarcoma.